drugset / Trial / NCT00615160
PTK/ZK in Disseminated Malignant Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy of PTK-ZK on metastatic melanoma either as a single agent treatment or in combination with standard chemotherapy according to RECIST criteria. Further to evaluate the safety and tolerability of PTK-ZK in patients with metastatic melanoma either as a single agent treatment or in combination with standard chemotherapy
Timeline
- Start
- 2006-12
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dacarbazine | Small molecule | 850 mg/m2 | Intravenous |
| Subject | vatalanib | Small molecule | 1250 mg | Oral |